Skip to main navigation Skip to search Skip to main content

Trabectedin Cardiotoxicity in Soft Tissue Sarcoma: A Case Series and Clinical Insights

  • David G Gent
  • , Nasim Ali
  • , Anna Olsson-Brown
  • , Gregory Y H Lip
  • , David J Wright
  • , Rebecca Dobson
  • University of Liverpool
  • Liverpool Heart and Chest Hospital NHS Foundation Trust
  • Clatterbridge Cancer Centre NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

Abstract

Trabectedin is a chemotherapeutic used to treat advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer. Although it is associated with a low incidence of cardiotoxicity, when this occurs it can be fatal or significantly compromise the quality of life in patients with advanced cancer. Here, we present a series of 4 cases where trabectedin-treated sarcoma patients developed cardiovascular complications. Similar to previous literature describing this association, all patients had prior treatment with anthracyclines and presented at different time points following treatment initiation. Each patient presented with exertional breathlessness and was found to have severely impaired left ventricular systolic function (ejection fraction ≤35%), and 1 patient had concurrent atrial fibrillation with a fast ventricular rate. All of the patients were treated with neurohormonal blockade, and a multi-disciplinary decision was made to stop trabectedin in 3 patients and continue in 1 patient. Two of the 4 patients had an improvement in their left ventricular systolic function. It is unclear what effect preceeding anthracycline or tyrosine kinase inhibitor treatment has in priming patients to develop cardiotoxicity in this setting. Our case series adds to the evidence surrounding this association and highlights that trabectedin-associated cardiotoxicity can present in an insidious fashion.

Original languageEnglish
Pages (from-to)950-959
Number of pages10
JournalCase Reports in Oncology
Volume15
Issue number3
DOIs
Publication statusPublished - 8 Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Arrhythmia
  • Cardiotoxicity
  • Heart failure
  • Trabectedin

Fingerprint

Dive into the research topics of 'Trabectedin Cardiotoxicity in Soft Tissue Sarcoma: A Case Series and Clinical Insights'. Together they form a unique fingerprint.

Cite this